Matthew Wiisanen, MD
Interventional Cardiology · Chattanooga, TNNPI 1215945001
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,344 of the $100,667 with a category attached, or 61.9%. Angiodynamics, Inc. accounts for 83.7% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2019 at $35,814 and has fallen 95.3% since, to $1,671 in 2025. Among interventional cardiology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 534 payments — averaging $188.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$84K
- Abbott$3K
- Medtronic$3K
- Boston Scientific$1K
- Inari Medical, Inc.$1K
- GE HealthCare$1K
- plus $6K from 40 others
Across 32 payments — averaging $1898.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$61K
What the payments were for
- Consulting fees$62,34462%
- Travel & lodging$18,19218%
- Food & beverage$19,94720%
- Education$1830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioVac$34,605
- AlphaVac$6,825
- COREVALVE EVOLUT R$1,577
- HeartMate Touch$1,000
- FLOWTRIEVER CATHETER, S$596
- CT THROMBECTOMY SYSTEM KIT$596
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$355
- Impella$279
- SAPIEN 3 Ultra RESILIA$157
- Resolute$131
- FARXIGA$124
- WATCHMAN Access System$119
- AMPLATZER$117
- CoreValve Evolut$116
- CardioMEMS HF System$116
- Relay Grafts$114
- GENERAL - STRUCTURAL HEART$108
- OPTICROSS$106
- SYMPLICITY G3$104
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$103
How this compares
$100,667 in reported general payments places this provider in the 90th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 96 | $91,522 |
| FarxigaDapagliflozin Propanediol | 115 | $89,073 |
| JardianceEmpagliflozin | 67 | $57,202 |
| EliquisApixaban | 64 | $48,760 |
| OzempicSemaglutide | 31 | $38,655 |
| XareltoRivaroxaban | 28 | $28,945 |
| BrilintaTicagrelor | 22 | $17,759 |
| Repatha SyringeEvolocumab | 27 | $15,563 |
| Repatha SureclickEvolocumab | 21 | $13,186 |
| VascepaIcosapent Ethyl | 11 | $6,605 |
| Prasugrel Hcl | 55 | $3,866 |
| Metoprolol Succinate | 196 | $2,130 |
| Ranolazine ErRanolazine | 15 | $1,990 |
| ClopidogrelClopidogrel Bisulfate | 188 | $1,763 |
| Rosuvastatin Calcium | 114 | $1,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $298 | $106,832137 claims |
| NovartisEntresto | $851 | $91,52296 claims |
| Boehringer IngelheimJardiance | $123 | $57,20267 claims |
| PfizerEliquis | $283 | $48,76064 claims |
| Novo NordiskOzempic | $126 | $38,65531 claims |
| Johnson & JohnsonXarelto | $190 | $28,94528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Chattanooga
- John GoldingChattanooga$21K
- Walter FewChattanooga$19K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.